Novartis Combines Stability, Innovation, and Shareholder Friendliness
Pharmaceutical stocks are less sensitive to economic cycles, making them an attractive core investment in any market environment.
The recent dividend increase to 3.50 CHF per share for the fiscal year 2024 marks the 28th consecutive increase.
Reading Time: 1 minute
Since May 2025, Novartis (SIX: NOVN) has been directly listed on German exchanges again. This makes purchases easier and more transparent for retail investors, as they no longer have to go through ADRs. At the same time, being based in Switzerland provides political stability, reasonable regulation, and currency strength. Novartis has future potential in key areas such as oncology, cell and gene therapies, rare diseases, and cardiovascular diseases. The company is among the strongest dividend-paying pharmaceutical stocks in Europe and is currently...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
